The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Table 5 Matches included in base case analysis

ID	Match 1	Match 2	Drug 1	Drug 2	PFS 1^a	PFS 2^a	HR^b
Within white network
1	Hou et al. [73]	Lacy et al. [74]	dex + len	dex + pom	8.3	4.8	0.58
Within black network
2	Fukushima et al. [72]	Terpos et al. [78]	bor + dex	dex + thal	16.8	8	0.48
3	Pantani et al. [76]	Terpos et al. [78]	bor + dex	dex + thal	8.7	8	0.92
Connecting both networks
4	Hou et al. [73]	Richardson et al. [77]	dex + len	bor + dex + pan	8.3	5.4	0.65
5	Lacy et al. [74]	Richardson et al. [77]	dex + pom	bor + dex + pan	4.8	5.4	1.13
6	Oehrlein et al. [75]	Pantani et al. [76]	dex + len	bor + dex	11.6	8.7	0.75
7	Oehrlein et al. [75]	Terpos et al. [78]	dex + len	dex + thal	11.6	8	0.69
8	Fukushima et al. [72]	Oehrlein et al. [75]	bor + dex	dex + len	16.8	11.6	0.69

bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat, HR hazard ratio, PFS progression free survival
^amedian
^bestimated from median PFS assuming exponential survival

ISSN: 1471-2288